Alzheimer's disease (AD) is a multifactorial disease. Risk factors such as aging, genetic factors, vascular diseases, infections, and environmental factors play roles in AD pathogenesis. Currently, only symptomatic treatments are available for AD interventions. Additional non-pharmacological and psychosocial management may also have some benefits. Disease-modifying therapies are still under development, while immunotherapy may be a viable option in the near future. These indicate that complex pathophysiology of AD may necessitate multimodal interventions.
The goal of this Research Topic is to present some multimodal diagnoses and interventions in AD, ranging from the current basic and clinical evidence for combinational therapies in the intervention of AD to the innovative clinical trial study designs that may be effective in testing early diagnosis and combinational interventions, and to the discussions about the mechanisms underlying AD multimodal interventions.
We welcome any types of manuscripts supported by the Journal–comprised of the Original Research Article, Brief Research Article, Review, Mini-review, and Meta-analysis, pertaining, but not limited to, the following themes involving in multimodal diagnosis and interventions in AD:
- Multimodal interventions in AD and risk individuals (mild cognitive impairment, subjective cognitive decline, late-life depression)
- Early diagnosis of AD
- Current basic and clinical evidence for AD treatment
- Innovative clinical trial study designs
- Mechanism for AD multimodal interventions
- Perspectives for the development of new diagnosis and therapies for AD
Alzheimer's disease (AD) is a multifactorial disease. Risk factors such as aging, genetic factors, vascular diseases, infections, and environmental factors play roles in AD pathogenesis. Currently, only symptomatic treatments are available for AD interventions. Additional non-pharmacological and psychosocial management may also have some benefits. Disease-modifying therapies are still under development, while immunotherapy may be a viable option in the near future. These indicate that complex pathophysiology of AD may necessitate multimodal interventions.
The goal of this Research Topic is to present some multimodal diagnoses and interventions in AD, ranging from the current basic and clinical evidence for combinational therapies in the intervention of AD to the innovative clinical trial study designs that may be effective in testing early diagnosis and combinational interventions, and to the discussions about the mechanisms underlying AD multimodal interventions.
We welcome any types of manuscripts supported by the Journal–comprised of the Original Research Article, Brief Research Article, Review, Mini-review, and Meta-analysis, pertaining, but not limited to, the following themes involving in multimodal diagnosis and interventions in AD:
- Multimodal interventions in AD and risk individuals (mild cognitive impairment, subjective cognitive decline, late-life depression)
- Early diagnosis of AD
- Current basic and clinical evidence for AD treatment
- Innovative clinical trial study designs
- Mechanism for AD multimodal interventions
- Perspectives for the development of new diagnosis and therapies for AD
